Media coverage

NASDAQ-Listed Enveric To Split Into Two Companies, One For Cannabinoids, One For Psychedelics

May 11, 2022  

Enveric Offers Investors Rare Exposure To Both Cannabis And Psychedelic Industries [Benzinga]

April 19, 2022

Bob Dagher, Chief Medical Officer at Enveric Biosciences [The Green Rush]

March 31, 2022

Inside the Race to Make Psychedelics ‘Mainstream Medicines’ [Endpoints News]

March 29, 2022

Five Companies Developing Second Generation Psychedelics For Mental Health [Benzinga]

March 24, 2022

Groundbreaking Trial to Explore Psychedelic Therapy for Cancer Distress [Psychedelic Health]

February 21, 2022

Groundbreaking trial to explore psychedelic therapy for cancer distress

Psilocybin For Cancer Related Distress: Enveric To Launch Clinical Trial In Partnership With University of Calgary [via Benzinga]

February 17, 2022

UCalgary to Collaborate on Clinical Trial Assessing Psychedelic Treatments and Cancer Related Distress [The Edmonton Journal]

February 17, 2022

Enveric Biosciences Files Provisional Patent for Cannabinoid + Celecoxib Conjugate EV104 after Successful Synthesis [IPO Edge]

February 8, 2022

Cannabis For Arthritis: Enveric Biosciences Files Patent On CBD Medication For Osteoarthritis [Benzinga]

February 8, 2022